Related Experiment Video

Updated: Mar 13, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Novel oral anticoagulants for acute coronary syndrome

April Robinson1, Delilah McCarty2, Janine Douglas2

  • 1Wingate University, 515 North Main Street, Wingate, NC 28174, USA a.robinson@wingate.edu.

Therapeutic Advances in Cardiovascular Disease
|October 22, 2016
PubMed

Insights

Novel oral anticoagulants (NOACs) are being explored for acute coronary syndrome (ACS) management. Ongoing studies will clarify the role of NOACs, balancing efficacy against bleeding risks in ACS patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Acute coronary syndrome (ACS) involves complex pathophysiology including plaque rupture and hypercoagulability.
  • Anticoagulants are crucial in ACS management, with warfarin having limited use.
  • Novel oral anticoagulants (NOACs) show promise but face challenges in ACS treatment.

Approach:

  • Investigating the role of anticoagulants in acute and post-acute phases of ACS.
  • Evaluating the efficacy and safety of NOACs in ACS patients.
  • Analyzing clinical trial data for NOACs like rivaroxaban and apixaban in ACS.

Key Points:

  • NOACs are being explored as alternatives to warfarin for ACS.
  • Increased bleeding risk with NOACs combined with dual antiplatelet therapy is a major concern.
  • Rivaroxaban is approved in Europe for ACS, but no NOACs are currently approved in the US.

Conclusions:

  • Further research is needed to establish the optimal role of NOACs in ACS management.
  • Ongoing trials may provide crucial evidence for the use of rivaroxaban and apixaban in ACS.
  • Balancing antithrombotic benefits with bleeding risks remains a key challenge for NOACs in ACS.

Keywords:
acute coronary syndromeanticoagulationantiplateletapixabandabigatranedoxabannovel oral anticoagulantsrivaroxabanthrombinwarfarin

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.4K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
365
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
376
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
449